Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

furosemide (unii: 7lxu5n7zo5) (furosemide - unii:7lxu5n7zo5) - tablet - 20 mg - furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. furosemide is particularly useful when an agent with greater diuretic potential is desired. oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone. furosemide is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

alvogen, inc - gadopentetate dimeglumine (unii: rh248g8v27) (gadopentetate - unii:v7ok6j19hq) - gadopentetate dimeglumine 469.01 mg in 1 ml - gadopentetate dimeglumine injection is indicated for use with magnetic resonance imaging (mri) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. gadopentetate dimeglumine injection has been shown to facilitate visualization of intracranial lesions including but not limited to tumors. gadopentetate dimeglumine is indicated for use with mri in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the head and neck. gadopentetate dimeglumine injection is indicated for use in mri in adults and pediatric patients (2 years of age and older) to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart). gadopentetate dimeglumine is contraindicated in patients with:

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

baxter healthcare corporation - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid - unii:33x04xa5at), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698) - sodium chloride 6 g in 1000 ml - lactated ringer’s irrigation is indicated for use as an arthroscopic irrigating fluid with endoscopic instruments during arthroscopic procedures requiring distension and irrigation of the knee, shoulder, elbow, or other bone joints. lactated ringer’s irrigation is contraindicated in patients with a known hypersensitivity to sodium lactate.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

sandoz inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide 0.5 mg in 2.5 ml - ipratropium bromide inhalation solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives. ipratropium bromide inhalation solution, 0.02% read complete instructions carefully before using. - twist open the top of one unit dose vial and squeeze the contents into the nebulizer reservoir. (figure 1). - connect the nebulizer reservoir to the mouthpiece or face mask (figure 2). - connect the nebulizer to the compressor. - sit in a comfortable, upright position; place the mouthpiece in your mouth (figure 3) or put on the face mask and turn on the compressor. if a face mask is used, care should be taken to avoid leakage around the mask as temporary blurring of visio

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

tarte inc - octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51) - octinoxate 2.2125 ml in 29.5 ml

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

fresenius kabi usa, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone acetate 1 mg - hailey fe 1/20 is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. oral contraceptives are highly effective. table i lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. table 1 lowest expected and typical failure rates during the first year of continuous use of a method % of women experiencing an unintended pregnancy in the first year of continuous use method lowest expected* typical** (no contraception) (85) (85) oral contraceptives       combined      progestin only 0.1 0.5 3 n/a*** n/a*** diaphragm with spermicidal cream or jelly 6 20 spermicides alone (foam, creams, gels, vaginal     suppositories, and vaginal film) 6 26 vaginal sponge       nulliparous    

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

baxter healthcare company - water (unii: 059qf0ko0r) (water - unii:059qf0ko0r) - sterile water for injection, usp is indicated in the aseptic preparation of parenteral admixtures. sterile water for injection, usp is a hemolytic agent due to its hypotonicity. therefore, it is contraindicated for intravenous administration without admixing.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - ethacrynic acid (unii: m5dp350vzv) (ethacrynic acid - unii:m5dp350vzv) - ethacrynic acid is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. all diuretics, including ethacrynic acid is contraindicated in anuria. if increasing electrolyte imbalance, azotemia, and/or oliguria occur during treatment of severe, progressive renal disease, the diuretic should be discontinued. in a few patients this diuretic has produced severe, watery diarrhea. if this occurs, it should be discontinued and not used again. until further experience in infants is accumulated, therapy with oral and parenteral ethacrynic acid is contraindicated. hypersensitivity to any component of this product.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

twi pharmaceuticals, inc. - hydroquinone (unii: xv74c1n1ae) (hydroquinone - unii:xv74c1n1ae) - hydroquinone usp, 4% time release cream is indicated for the gradual treatment of ultraviolet induced dyschromia and discoloration (such as chloasma, melasma, freckles, and senile lentigines) resulting from the use of oral contraceptives, pregnancy, hormone replacement therapy, or skin trauma. prior history of sensitivity or allergic reaction to hydroquinone or to any of the ingredients of the product. the safety of topical hydroquinone use during pregnancy or on children (12 years and under) has not been established.